In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk's STEP trial programme for once-weekly GLP-1 agonist Wegovy (semaglutide) revealed a reduction in body weight of around 12%, suggesting greater potency for Lilly's dual-acting drug ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Eli Lilly’s profit doubled in the fourth quarter ... They compete with Ozempic and Wegovy from the Danish drugmaker Novo Nordisk, which also reported strong sales growth on Wednesday.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...